Equities

Quantum Genomics SA

Quantum Genomics SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)0.0295
  • Today's Change0.008 / 35.94%
  • Shares traded17.64m
  • 1 Year change-79.43%
  • Beta0.7544
Data delayed at least 15 minutes, as of Sep 20 2024 16:36 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Quantum Genomics SA is a France-based company. The Company is a biopharmaceutical company dedicated to developing new therapies for unmet medical needs in cardiovascular disease, including high blood pressure and heart failure. Its main activity is in research and development of new therapies for the treatment of hypertension, BAPAI (Brain Aminopeptidase A Inhibitors) oriented in the field of cardiovascular diseases, especially high blood pressure and heart failure. The Company also co-develops products with academic teams, biotechnological research entities, and some of the pharmaceutical and bio-science companies. The Company is involved in four research programs. Quantum Genomics also collaborates with Center for Clinical Investigation 9201 APHP / INSERM of the Georges Pompidou European Hospital in Paris, among others.

  • Revenue in EUR (TTM)10.06k
  • Net income in EUR-3.17m
  • Incorporated2005
  • Employees3.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Theravet SA-100.00bn-100.00bn354.61k--------------------------------------------------------------
Quantum Genomics SA10.06k-3.17m1.51m3.00--1.73--150.37-0.091-0.0910.00030.01250.0007--0.00163,353.33-23.14-60.77-95.19-102.24-14,205.07-3,548.91-31,520.38-3,374.13---146.530.8615---98.34--87.28------
Biophytis SA0.00-17.03m1.85m22.00---------14.37-14.370.00-1.490.00----0.00-100.31-97.52-1,481.81-487.25-----------5.462.27------29.69--14.25--
GeNeuro SA0.00-14.76m1.93m19.00---------0.594-0.5940.00-0.55480.00----0.00-165.51-96.43-356.72-185.61---------------------20.96---20.13--
Medesis Pharma SA0.00-3.96m2.47m10.00---------0.7916-0.79160.00-0.90710.000.3139-----206.12-126.10---300.50--70.78---2,552.190.467-26.37---------44.04------
IntegraGen SA12.54m-171.40k3.53m55.00--1.73131.740.2817-0.025-0.0251.900.30411.4712.064.06227,953.30-2.01-1.93-4.78-4.4166.4165.11-1.37-1.511.57--0.3587---4.7812.61-4,783.19------
Theranexus SA0.00-6.83m4.66m19.00--2.10-----1.09-1.090.000.28630.00----0.00-70.79-42.66-82.29-47.97-----------1,058.680.6212-------3.97---33.23--
Acticor Biotech SA0.00-18.64m5.36m28.00---------1.55-1.550.00-0.40280.00----0.00-164.53---568.29-------------19.8510.47-------17.40------
Data as of Sep 20 2024. Currency figures normalised to Quantum Genomics SA's reporting currency: Euro EUR

Institutional shareholders

0.00%Per cent of shares held by top holders
HolderShares% Held
Lemanik Asset Management SAas of 31 Dec 20230.000.00%
Data from 31 Jul 2024 - 31 Jul 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.